BIOREM INC (BRM.CA) Fundamental Analysis & Valuation

TSX-V:BRM • CA09068G1046

Current stock price

2.435 CAD
-0.02 (-0.61%)
Last:

This BRM.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. BRM.CA Profitability Analysis

1.1 Basic Checks

  • BRM had positive earnings in the past year.
  • In the past year BRM had a positive cash flow from operations.
  • Each year in the past 5 years BRM has been profitable.
  • Each year in the past 5 years BRM had a positive operating cash flow.
BRM.CA Yearly Net Income VS EBIT VS OCF VS FCFBRM.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1M -1M 2M 3M 4M

1.2 Ratios

  • The Return On Assets of BRM (7.60%) is better than 91.30% of its industry peers.
  • BRM has a Return On Equity of 17.30%. This is amongst the best in the industry. BRM outperforms 86.96% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 15.89%, BRM belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • BRM had an Average Return On Invested Capital over the past 3 years of 25.13%. This is significantly above the industry average of 6.08%.
  • The 3 year average ROIC (25.13%) for BRM is well above the current ROIC(15.89%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 7.6%
ROE 17.3%
ROIC 15.89%
ROA(3y)9.17%
ROA(5y)8.76%
ROE(3y)32.25%
ROE(5y)35.65%
ROIC(3y)25.13%
ROIC(5y)23.46%
BRM.CA Yearly ROA, ROE, ROICBRM.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

1.3 Margins

  • The Profit Margin of BRM (6.08%) is better than 73.91% of its industry peers.
  • In the last couple of years the Profit Margin of BRM has grown nicely.
  • The Operating Margin of BRM (8.82%) is better than 73.91% of its industry peers.
  • BRM's Operating Margin has improved in the last couple of years.
  • BRM's Gross Margin of 24.25% is in line compared to the rest of the industry. BRM outperforms 43.48% of its industry peers.
  • In the last couple of years the Gross Margin of BRM has grown nicely.
Industry RankSector Rank
OM 8.82%
PM (TTM) 6.08%
GM 24.25%
OM growth 3Y7.19%
OM growth 5YN/A
PM growth 3Y15.35%
PM growth 5YN/A
GM growth 3Y1.79%
GM growth 5Y2.67%
BRM.CA Yearly Profit, Operating, Gross MarginsBRM.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BRM.CA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BRM is creating value.
  • Compared to 1 year ago, BRM has more shares outstanding
  • The number of shares outstanding for BRM has been reduced compared to 5 years ago.
  • Compared to 1 year ago, BRM has an improved debt to assets ratio.
BRM.CA Yearly Shares OutstandingBRM.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BRM.CA Yearly Total Debt VS Total AssetsBRM.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

  • An Altman-Z score of 3.79 indicates that BRM is not in any danger for bankruptcy at the moment.
  • BRM has a Altman-Z score of 3.79. This is amongst the best in the industry. BRM outperforms 91.30% of its industry peers.
  • BRM has a debt to FCF ratio of 1.39. This is a very positive value and a sign of high solvency as it would only need 1.39 years to pay back of all of its debts.
  • BRM has a better Debt to FCF ratio (1.39) than 95.65% of its industry peers.
  • A Debt/Equity ratio of 0.20 indicates that BRM is not too dependend on debt financing.
  • BRM's Debt to Equity ratio of 0.20 is amongst the best of the industry. BRM outperforms 86.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF 1.39
Altman-Z 3.79
ROIC/WACC2.01
WACC7.91%
BRM.CA Yearly LT Debt VS Equity VS FCFBRM.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

  • BRM has a Current Ratio of 1.89. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
  • BRM has a Current ratio of 1.89. This is amongst the best in the industry. BRM outperforms 82.61% of its industry peers.
  • BRM has a Quick Ratio of 1.73. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
  • BRM's Quick ratio of 1.73 is fine compared to the rest of the industry. BRM outperforms 78.26% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.73
BRM.CA Yearly Current Assets VS Current LiabilitesBRM.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BRM.CA Growth Analysis

3.1 Past

  • The earnings per share for BRM have decreased strongly by -64.28% in the last year.
  • BRM shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 32.08% yearly.
  • BRM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.88%.
  • The Revenue has been growing by 12.63% on average over the past years. This is quite good.
EPS 1Y (TTM)-64.28%
EPS 3Y32.08%
EPS 5YN/A
EPS Q2Q%-47.19%
Revenue 1Y (TTM)-24.88%
Revenue growth 3Y15.2%
Revenue growth 5Y12.63%
Sales Q2Q%-24.4%

3.2 Future

  • BRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.40% yearly.
  • Based on estimates for the next years, BRM will show a quite strong growth in Revenue. The Revenue will grow by 10.68% on average per year.
EPS Next Y5.26%
EPS Next 2Y21.4%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.42%
Revenue Next 2Y10.68%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BRM.CA Yearly Revenue VS EstimatesBRM.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
BRM.CA Yearly EPS VS EstimatesBRM.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0.05 0.1 0.15 0.2 0.25

More info and screens

Find the best growth stocksShow best growing peers

6

4. BRM.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 22.14, BRM is valued on the expensive side.
  • BRM's Price/Earnings ratio is a bit cheaper when compared to the industry. BRM is cheaper than 78.26% of the companies in the same industry.
  • BRM is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.78, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 8.44, the valuation of BRM can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, BRM is valued cheaply inside the industry as 91.30% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of BRM to the average of the S&P500 Index (23.54), we can say BRM is valued rather cheaply.
Industry RankSector Rank
PE 22.14
Fwd PE 8.44
BRM.CA Price Earnings VS Forward Price EarningsBRM.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BRM is valued a bit cheaper than 78.26% of the companies in the same industry.
  • 78.26% of the companies in the same industry are more expensive than BRM, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 17.64
EV/EBITDA 9.56
BRM.CA Per share dataBRM.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BRM does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of BRM may justify a higher PE ratio.
  • BRM's earnings are expected to grow with 21.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.21
PEG (5Y)N/A
EPS Next 2Y21.4%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BRM.CA Dividend Analysis

5.1 Amount

  • No dividends for BRM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BRM.CA Fundamentals: All Metrics, Ratios and Statistics

BIOREM INC

TSX-V:BRM (4/10/2026, 7:00:00 PM)

2.435

-0.02 (-0.61%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryCommercial Services & Supplies
Earnings (Last)11-26
Earnings (Next)04-14
Inst Owners0.16%
Inst Owner ChangeN/A
Ins Owners2%
Ins Owner ChangeN/A
Market Cap39.25M
Revenue(TTM)34.73M
Net Income(TTM)2.11M
Analysts84.44
Price Target3.57 (46.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 22.14
Fwd PE 8.44
P/S 1.13
P/FCF 17.64
P/OCF 15.27
P/B 3.22
P/tB 3.22
EV/EBITDA 9.56
EPS(TTM)0.11
EY4.52%
EPS(NY)0.29
Fwd EY11.84%
FCF(TTM)0.14
FCFY5.67%
OCF(TTM)0.16
OCFY6.55%
SpS2.15
BVpS0.76
TBVpS0.76
PEG (NY)4.21
PEG (5Y)N/A
Graham Number1.37
Profitability
Industry RankSector Rank
ROA 7.6%
ROE 17.3%
ROCE 20.97%
ROIC 15.89%
ROICexc 37.09%
ROICexgc 37.09%
OM 8.82%
PM (TTM) 6.08%
GM 24.25%
FCFM 6.41%
ROA(3y)9.17%
ROA(5y)8.76%
ROE(3y)32.25%
ROE(5y)35.65%
ROIC(3y)25.13%
ROIC(5y)23.46%
ROICexc(3y)41.23%
ROICexc(5y)N/A
ROICexgc(3y)41.23%
ROICexgc(5y)N/A
ROCE(3y)33.17%
ROCE(5y)30.97%
ROICexgc growth 3Y-30.69%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.69%
ROICexc growth 5YN/A
OM growth 3Y7.19%
OM growth 5YN/A
PM growth 3Y15.35%
PM growth 5YN/A
GM growth 3Y1.79%
GM growth 5Y2.67%
F-Score4
Asset Turnover1.25
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF 1.39
Debt/EBITDA 0.67
Cap/Depr 66.81%
Cap/Sales 0.99%
Interest Coverage 250
Cash Conversion 71.82%
Profit Quality 105.47%
Current Ratio 1.89
Quick Ratio 1.73
Altman-Z 3.79
F-Score4
WACC7.91%
ROIC/WACC2.01
Cap/Depr(3y)93.69%
Cap/Depr(5y)79.96%
Cap/Sales(3y)1.3%
Cap/Sales(5y)1.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-64.28%
EPS 3Y32.08%
EPS 5YN/A
EPS Q2Q%-47.19%
EPS Next Y5.26%
EPS Next 2Y21.4%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-24.88%
Revenue growth 3Y15.2%
Revenue growth 5Y12.63%
Sales Q2Q%-24.4%
Revenue Next Year5.42%
Revenue Next 2Y10.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-60.2%
EBIT growth 3Y23.48%
EBIT growth 5YN/A
EBIT Next Year33.62%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.22%
FCF growth 3Y-3.66%
FCF growth 5Y6.73%
OCF growth 1Y-18.62%
OCF growth 3Y-0.86%
OCF growth 5Y7.83%

BIOREM INC / BRM.CA Fundamental Analysis FAQ

What is the fundamental rating for BRM stock?

ChartMill assigns a fundamental rating of 7 / 10 to BRM.CA.


What is the valuation status of BIOREM INC (BRM.CA) stock?

ChartMill assigns a valuation rating of 6 / 10 to BIOREM INC (BRM.CA). This can be considered as Fairly Valued.


Can you provide the profitability details for BIOREM INC?

BIOREM INC (BRM.CA) has a profitability rating of 9 / 10.


Can you provide the PE and PB ratios for BRM stock?

The Price/Earnings (PE) ratio for BIOREM INC (BRM.CA) is 22.14 and the Price/Book (PB) ratio is 3.22.


Can you provide the financial health for BRM stock?

The financial health rating of BIOREM INC (BRM.CA) is 8 / 10.